Arcturus Therapeutics updates financial calendar with upcoming Q2 results release and conference callPUBT·5 hours agoARCT-0.17%
Cut the Earnings Season Noise: From AI Washing to Real Cash in 10 Outlier StocksGlobal Report·16 hours agoHTFL+0.87%ENVA-1.16%
The Value Chain Dictates the Outcome: From Defense Platforms to Biotech AggregatorsGlobal Report·Jul 21 at 04:13 AMSMJF+0.36%LHX+0.57%
Amova Asset Management Americas Inc. Grows Stock Holdings in Arcturus Therapeutics Holdings Inc. $ARCTMarket Beat·Jul 21 at 02:13 AMARCT-0.17%
How New Forensics and mRNA Partnerships at Thermo Fisher Scientific (TMO) Have Changed Its Investment StorySimplywall·Jul 15 at 12:12 PMTMO+3.02%ARCT-0.17%
Biotech Reorganizes While Industrials and Consumer Discretionary Navigate Pricing PressuresGlobal Report·Jul 14 at 06:47 AMARCT-0.17%MTNB-11.75%
How Investors May Respond To Thermo Fisher Scientific (TMO) Deepening Its Role In Late‑Stage mRNA ManufacturingSimplywall·Jul 5 at 03:01 PMTMO+3.02%ARCT-0.17%
Thermo Fisher, Arcturus partner on Phase III ARCT-032 cystic fibrosis trialWorldPharmaceuticals·Jul 3 at 04:43 AMTMO+3.02%ARCT-0.17%
Arcturus Therapeutics partners with Thermo Fisher to support Phase 3 development of cystic fibrosis therapy ARCT-032PUBT·Jul 2 at 06:00 AMARCT-0.17%TMO+3.02%
